Aflibercept

Active ingredient description

Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Aflibercept
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX44
Aflibercept
S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA05

Medicines

Aflibercept is the active ingredient of these drugs:

Drug
Countries

Australia Austria Canada Cyprus Estonia

Brazil

Austria Brazil Cyprus Estonia Finland

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)

Unique ingredient identifier (UNII)

15C2VL427D - AFLIBERCEPT

CAS registry number

862111-32-8 - aflibercept

SNOMED-CT

703840003 - Aflibercept (substance)